Obesity-drug developer BioAge Labs Inc. gained about 20% after its initial public offering on Thursday, while natural-gas ...

(Reuters) -Shares of BKV rose 3.1% in their debut on the New York Stock Exchange on Thursday, giving the U.S. natural gas ...

Texas-based Barnett Shale driller prices below the estimated range, while obesity-drug developer BioAge prices midrange ahead ...

Headlines,BKV made a successful debut on the New York Stock Exchange, achieving a significant market capitalization.,The ...

Texas-based Barnett Shale driller BKV Inc. priced below the estimated range, while obesity-drug developer BioAge Labs Inc. priced midrange ahead of their first day of trading on Thursday. As the ...

Natural gas producer BKV Corp said on Wednesday it had raised $270 million in its U.S. initial public offering.

The U.S. IPO market has bounced back strongly in 2024 after a nearly two-year dry spell, driven by receding recession fears ...

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

category Natgas producer BKV valued at $1.56 bln in NYSE debut 3:34 PM UTC · Updated ago category Chevron agrees Hess CEO ...

As the company is focused on developing treatments for autoimmune diseases, it is also developing MAU868, a monoclonal ...

BKV shares rose by 3.1% on their New York Stock Exchange debut on Thursday. This gives the U.S. Natural Gas Producer a market cap of $1.56 Billion.